Epilepsy is one of the most frequent neurologic disorders. The main aim of epilepsy treatment is to improve the quality of life, and to reduce epileptic seizures. Epilepsy is described as drug resistant if adequate trials of two tolerated and appropriately chosen and used treatments fail to achieve sustained seizure freedom. In Poland, 400,000 people suffer from epilepsy, and 30% of them have drug-resistant epilepsy. Surgical treatment is available for only some of these patients. The pursuit for new methods of alternative treatment continues, with neurofeedback seemingly emerging as one of viable options. Neurofeedback is a training method based on biofeedback, which can be described as providing information about the changes of the physiological signals to the trained person. In essence, neurofeedback takes place, if the bioelectrical activity of the brain (EEG) is the signal registered during the biofeedback training. The aim of this article is to present the knowledge regarding the use of SMR neurofeedback in the treatment of resistant epilepsy. In 1972, Sterman and Friar, encouraged by the positive results of studies in animals, for the first time attempted to use neurofeedback for the treatment of drug-resistant epilepsy. In the last decade, two independent meta-analyses were published. It seems that SMR neurofeedback should be considered as adjunctive method of treatment in patients with resistant epilepsy, particularly in cases where other methods have failed. More randomised controlled studies are needed to confirm the efficacy of this method of treatment. The directions of future studies have been highlighted in the article.